Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Key Points

Key points are not available for this paper at this time.

Abstract

Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Key Points

Abstract

Cite This Study